Soleno Therapeutics (NASDAQ:SLNO) saw its stock climb 14% following news that Acadia Pharmaceuticals’ (NASDAQ:ACAD) Phase 3 trial for a Prader-Willi syndrome therapy failed to meet its primary endpoint.
The COMPASS PWS trial from Acadia, which tested intranasal carbetocin (ACP-101) for hyperphagia in Prader-Willi syndrome, showed no statistically significant difference from placebo across secondary measures. As a result, Acadia announced it would discontinue development of ACP-101 for this indication.
With the setback for Acadia, Soleno faces less competition in the Prader-Willi treatment market. Wells Fargo analyst Derek Archila highlighted the potential upside for Soleno, noting: “SLNO remains the SOC [standard of care] in PWS, and the only drug approved” for the condition.
Archila added that the next Phase 3 competitor data is not expected until the third quarter of 2026 from ARD-101, with some Phase 2 results from Rhythm Pharmaceuticals’ IMCIVREE anticipated by the end of 2025.
Stifel analyst James Condulis described the failed trial as a “nice clearing event” that could help Acadia shares rebound after recent declines, while emphasizing that the development reinforces Soleno’s market position in Prader-Willi syndrome treatments.
Soleno Therapeutics stock price
Acadia Pharmaceuticals stock price
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.